Loading...
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
BACKGROUND: After two studies reporting response rates higher than 70% in HER2-positive metastatic breast cancer with weekly trastuzumab and vinorelbine, we planned a phase 2 study to test activity of the same combination, with trastuzumab given every 3 weeks. METHODS: Patients with HER2-positive me...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2007
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1832208/ https://ncbi.nlm.nih.gov/pubmed/17374151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-7-50 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|